Drug Insight: different mechanisms of action of tumor necrosis factor antagonists—passive-aggressive behavior?

被引：0

作者：

William FC Rigby

机构：

[1] WFC Rigby is a Professor of Medicine,

[2] Microbiology and Immunology at Dartmouth Medical School,undefined

[3] Lebanon,undefined

[4] NH,undefined

[5] USA.,undefined

来源：

Nature Clinical Practice Rheumatology | 2007年 / 3卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Etanercept, adalimumab and infliximab all specifically antagonize tumor necrosis factor (TNF), but with differential clinical efficacy. Differences in their pharmacology and mechanisms of action, and disease heterogeneity, might account for this therapeutic disparity, as might reverse signaling by transmembrane TNF in response to anti-TNF antibodies, all of which are reviewed here.

引用

页码：227 / 233

页数：6

共 50 条

[1] Drug Insight: different mechanisms of action of tumor necrosis factor antagonists - passive-aggressive behavior?
Rigby, William F. C.
NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2007, 3 (04): : 227 - 233
[2] Mechanisms of action of tumor necrosis factor antagonists and granulomatous infections
Beenhouwer, D
Wallis, R
Broder, M
Furst, DE
JOURNAL OF RHEUMATOLOGY, 2004, 31 (10) : 1888 - 1892
[3] Mechanism of action of tumor necrosis factor antagonists
Keystone, EC
Dinarello, CA
JOURNAL OF RHEUMATOLOGY, 2005, 32 : 1 - 2
[4] Distinct mechanisms of action of tumor necrosis factor antagonists: What are the clinical implications?
Rigby, WFC
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2005, 34 (05) : 1 - 2
[5] Drug insight:: Antagonists of tumor-necrosis factor-α in the treatment of inflammatory bowel disease
Chang, JT
Lichtenstein, GR
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2006, 3 (04): : 220 - 228
[6] Drug Insight: antagonists of tumor-necrosis factor-α in the treatment of inflammatory bowel disease
John T Chang
Gary R Lichtenstein
Nature Clinical Practice Gastroenterology & Hepatology, 2006, 3 : 220 - 228
[7] Tumor necrosis factor antagonists: Different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection
Furst, Daniel E.
Wallis, Robert
Broder, Michael
Beenhouwer, David O.
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2006, 36 (03) : 159 - 167
[8] MECHANISMS OF TUMOR-NECROSIS-FACTOR ACTION
SCHUTZE, S
MACHLEIDT, T
KRONKE, M
SEMINARS IN ONCOLOGY, 1992, 19 (02) : 16 - 24
[9] Mechanisms of cell death induced by tumor necrosis factor antagonists
Khare, T. Arora
Stevens, S. R.
Louie, J. S.
Kohno, T.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2006, 126 : 120 - 120
[10] Tumor necrosis factor:: clinical use and mechanisms of action
Rüegg, C
Dormond, O
Oguey, D
Lejeune, FJ
DRUG RESISTANCE UPDATES, 2000, 3 (05) : 271 - 276

← 1 2 3 4 5 →